A study of plasma bicalutamide concentrations in hemodialysis patients.

Fumio Ito, Nobuyuki Goya, Hayakazu Nakazawa, Toshiaki Suzuki, Keiko Suzuki, Kazuo Kubo, Takeshi Kihara

Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan. fitour @ dnh.twmu.ac.jp

Urologia internationalis 2012

filter terms:

Bicalutamide is an anti-androgen that is used worldwide to treat prostate cancer (CaP). However, there are no data on blood bicalutamide concentrations in hemodialysis (HD) patients with CaP. Therefore, we investigated the plasma levels of bicalutamide during the peridialysis period in this population. The study group included 5 HD patients with CaP who had been treated with bicalutamide (80 mg/day) for at least 3 months. Blood samples were taken during and between HD sessions and the plasma concentrations of the active R enantiomer (R-bicalutamide) were assessed using an HPLC assay. The plasma R-bicalutamide levels on the non-dialysis day were measured in 2 patients (patients 1 and 2) immediately before dosing and 8 and 24 h after dosing. These levels were 18,730, 19,090 and 19,420 ng/ml (patient 1), and 4,522, 4,581, and 5,296 ng/ml (patient 2), respectively. The mean plasma levels of R-bicalutamide in all 5 subjects just before HD, and 2 and 4 h after the start of HD were 8,726, 9,354 and 10,068 ng/ml, respectively. These results show that bicalutamide does not accumulate and is not diluted in the blood circulation of HD patients when given at the normal dosage used in the general population. Copyright © 2012 S. Karger AG, Basel.

Citation

Fumio Ito, Nobuyuki Goya, Hayakazu Nakazawa, Toshiaki Suzuki, Keiko Suzuki, Kazuo Kubo, Takeshi Kihara. A study of plasma bicalutamide concentrations in hemodialysis patients. Urologia internationalis. 2012;89(2):162-5